The Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.

Regulatory & Legal

VALIANTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

NSE has asked Valiant Laboratories to explain why segment-wise revenue details were not submitted along with its financial results for the quarter ended 30 September 2025. This is a procedural compliance query under SEBI's Listing Regulations. The company's response is still awaited. The company has not been penalised, and no enforcement action has been mentioned.

Likely market impact

This is a routine exchange clarification and not a punitive action. However, repeated non-compliance with disclosure norms can attract scrutiny and may affect investor confidence in the company's reporting practices.